Tai Chi for Reducing Aromatase Inhibitor-Induced Arthralgia

Official record

Identifier

NCT07737951

Recruiting locations

country

United States

Interventions studied

Tai ChiHealth Education

Lead sponsor

Thomas Jefferson University

Target enrolment

40 participants

Study type

INTERVENTIONAL

Phase

Not applicable

Status

Recruiting

First posted

Jul 30, 2026

Last updated on the registry

Aug 14, 2026

Age

18 Years

Sex

FEMALE

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

-Individuals must meet all the following inclusion criteria in order to be eligible to participate in the study:

* Age ≥18 years
* Diagnosis of stage I-III hormone receptor-positive breast cancer
* Postmenopausal
* Currently receiving an aromatase inhibitor (anastrozole, letrozole, or exemestane) or within 5 years of initiation
* Report joint pain that started or worsened after initiation of AI therapy
* Report worst pain in the past week ≥3 on the BPI (0-10 scale)
* Able to complete study procedures in English
* Willing to be randomized to an intervention or attention control group and adhere to study procedures

Exclusion Criteria:

-An individual who meets any of the following criteria will be excluded from participation in this study:

* Undergoing active cancer treatment (excluding endocrine therapy)
* Uncontrolled cardiac or pulmonary disease that would limit safe participation
* Currently engaged in regular structured moderate- or vigorous-intensity exercise (e.g., brisk walking, jogging/running, cycling, swimming, aerobic classes, or resistance training) totaling ≥150 minutes per week over the past 3 months
* Currently participating in Tai Chi, yoga, Pilates, or other structured mind-body practice ≥2 times per week over the past 3 months
* Joint pain due to inflammatory arthritic conditions
* Recent surgery or joint injection within the past 4-6 weeks
* Initiation or dose change of corticosteroids or opioids within the past 4 weeks
* Planned discontinuation of AI therapy within the next 6 months
* This study is limited to women with breast cancer, as \<1% of cases occur in men and data on AIIA in male patients are limited

Indexed under

Breast Cancer